Warning: Table 'themoney_2011new.access' doesn't exist query: SELECT 1 FROM access WHERE type = 'host' AND LOWER('') LIKE LOWER(mask) AND status = 0 LIMIT 0, 1 in /home/themoney/public_html/includes/database.mysql.inc on line 135

Warning: session_start(): Cannot send session cookie - headers already sent by (output started at /home/themoney/public_html/includes/database.mysql.inc:135) in /home/themoney/public_html/includes/bootstrap.inc on line 1165

Warning: session_start(): Cannot send session cache limiter - headers already sent (output started at /home/themoney/public_html/includes/database.mysql.inc:135) in /home/themoney/public_html/includes/bootstrap.inc on line 1165

Warning: Cannot modify header information - headers already sent by (output started at /home/themoney/public_html/includes/database.mysql.inc:135) in /home/themoney/public_html/includes/bootstrap.inc on line 729

Warning: Cannot modify header information - headers already sent by (output started at /home/themoney/public_html/includes/database.mysql.inc:135) in /home/themoney/public_html/includes/bootstrap.inc on line 730

Warning: Cannot modify header information - headers already sent by (output started at /home/themoney/public_html/includes/database.mysql.inc:135) in /home/themoney/public_html/includes/bootstrap.inc on line 731

Warning: Cannot modify header information - headers already sent by (output started at /home/themoney/public_html/includes/database.mysql.inc:135) in /home/themoney/public_html/includes/bootstrap.inc on line 732
Latest Pfizer news and updates

Money Matters - Simplified


Sun Pharma shares clamber up! Then why net loss?

Now that’s surprising!! After admitting to a net loss of almost Rs. 1,276 crores in the June quarter, the top drug maker in India, Sun Pharmaceuticals shares have shown to be jumping up 9%!

Pharma Ups the Dividend Ante

 There's no way to sugarcoat this: It was not a pretty year for pharmaceutical companies. While the S&P saw substantial gains over the last year, with the exception of Bristol-Myers Squibb (NYSE: BMY) and Novartis (NYSE: NVS), every other major pharmaceutical company listed on the U.S. exchange saw their shares decrease. And neither of the two that were in positive territory actually surpassed the S&P 500.


Pfizer Diagnoses Fido, Too

Pfizer (NYSE: PFE) is jumping into the diagnostic business with all four paws. The company announced yesterday that it's purchasing Synbiotics to gain access to its veterinary immunodiagnostics business.

The Best Stocks for 2011: Dendreon


This article is part of our "Best Stocks for 2011" series where our Foolish writers pick their top stock ideas for the year ahead. Click here to see a review of last year's picks and our 12 recommendations for the year ahead.

Will the FDA Be Kind to MannKind?

MannKind (Nasdaq: MNKD) is scheduled to get a late present from the Food and Drug Administration on or before Dec. 29, when the agency decides whether to approve its inhaled insulin product, Afrezza. But the contents of the package -- an approval or a lump of coal -- remain to be seen.

4 Drugmakers, 5 Deals, Christmas Is Here

It looks like a lot of people in the business development offices at pharmaceutical companies were looking to get their work done before taking off for the holidays. Check out all the deals announced yesterday.

Options? Are You Nuts?!

So how about that stock market rally? You think the recent dip was a speed bump? Or are we looking at another big drop sometime soon?

2 Smart Sectors for 2011

As the year draws to a close, investors have started looking forward to 2011. With the market having made substantial gains over the past two years, it's more important than ever to make sure you identify investments that still have room to run. Otherwise, you could easily see the rebound you've probably enjoyed in your portfolio since the market meltdown reverse itself.

4 Dividend Stocks Showing You the Money

Dividend checks continue to get fatter in Corporate America, as more companies jack up their distribution rates. Readers of the Income Investor newsletter can certainly appreciate that kind of thinking. Let's take a closer look at some of the companies that inched their payouts higher this past week.

MannKind Shares Plunged: What You Need to Know

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.What: Shares of biopharmaceutical company MannKind (Nasdaq: MNKD) went on a roller-coaster ride today climbing slowly throughout the day before crashing 10% late in the day.